Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Priority Review Granted by FDA to Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
mTOR1/2 Inhibitor Plus Fulvestrant Under Study in Metastatic Breast Cancer
FDA Brief: Fast Track Designation Granted to Enobosarm in Metastatic Breast Cancer
T-DXd Versus T-DM1 in Metastatic Breast Cancer: Subgroup Analyses From DESTINY-Breast03
How Does Pembrolizumab Impact the Tumor Microenvironment of Triple-Negative Breast Cancer?
How Useful Are Genomic Analyses for Patients With Metastatic Breast Cancer?
Advanced Breast Cancer: Overall Survival Subgroup Analysis From MONALEESA-2 Trial
Can Brain White Matter Microstructure Cause Cognitive Decline in Patients With Breast Cancer?
Are Black Women More Likely Than Others to Develop Breast Cancer–Related Lymphedema?
SABCS 2021: Update From Phase III Trial of Oral SERD in Advanced Breast Cancer
SABCS 2021: Menopausal Status and Outcomes of Endocrine Therapy With or Without Chemotherapy for Breast Cancer
Final Results of Phase II Trial of Eftilagimod Alpha in Metastatic Breast Cancer
SABCS 2021: KEYNOTE-355 Final Results of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
SABCS 2021: Final Results of PALLAS Trial on Palbociclib Plus Endocrine Therapy in HER2-Negative Breast Cancer
SABCS 2021: Neoadjuvant and Adjuvant Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
FDA Grants Priority Review to Olaparib for HER2-Negative High-Risk Breast Cancer
SITC 2021: Anti-CD47 Immunotherapy Under Study for Reducing Breast Cancer Brain Metastasis
Phase III Trial Explores Internal Mammary Node Irradiation in Node-Positive Breast Cancer
SITC 2021: Cellular Study of Malignant Pleural Effusions and Metastatic Breast Cancer
Appropriate Timing of Radiotherapy After Mastectomy for High-Risk Breast Cancer
Is Breast Cancer Associated With an Increased Incidence of Atrial Fibrillation?
30-Year Analysis of Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer
ASTRO 2021: Accelerated Partial-Breast Irradiation Fractions and Breast Cosmesis
Can Systems-Based Intervention Reduce Racial Gaps in Treatment of Breast Cancer?
ASTRO 2021: Phase III Trial of Hypofractionated Radiotherapy for Localized Breast Cancer
ASTRO 2021: Targeted Radiation Therapy for Oligoprogressive Metastatic Breast Cancers
FDA Adds Restrictions and Approves New Labeling for Breast Implants
ASTRO 2021: Novel Once-Daily Partial Breast Irradiation Regimen Focus of Phase II Trial
Extended Letrozole Therapy in Postmenopausal Patients With Breast Cancer: How Long Is Long Enough?
Novel ATR Inhibitor in Breast Cancer: Phase I Data Suggest Phase II Trial Warranted
ASTRO 2021: COVID-19 Pandemic and Radiotherapy Patterns for Breast Cancer
How a Novel Prediction Model May Help to Reduce False-Positive Recalls in Breast Cancer Screening
Updated Survival Results From DESTINY-Breast01 of T-DXd in Metastatic Breast Cancer
Adding Carboplatin With or Without Veliparib to Neoadjuvant Chemotherapy: Long-Term Follow-up in Triple-Negative Breast Cancer
Abemaciclib Plus Endocrine Therapy Approved by FDA for Early Breast Cancer
Breakthrough Therapy Designation Granted for T-DXd in HER2-Positive Breast Cancer
ESMO 2021: Interim Phase II Results With Dalpiciclib Plus Pyrotinib in HER2-Positive Breast Cancer
ESMO 2021: Subgroup Analysis of Asian Patients Treated With T-DM1 for Breast Cancer
ESMO 2021: Update From KEYNOTE-355 on Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ESMO 2021: Neoadjuvant Giredestrant Versus Anastrozole in Postmenopausal Women With Early Breast Cancer
ESMO 2021: Long-Term Overall Survival With Letrozole Plus Ribociclib in Advanced Breast Cancer
ESMO 2021: DESTINY-Breast03 Trial of T-DXd Versus T-DM1 in HER2-Positive Breast Cancer
ESMO 2021: How Does 6 Months of Trastuzumab Measure Up to Longer Treatment in Early Breast Cancer?
ESMO 2021: COVID-19 Vaccination in Patients With Breast Cancer
Are Genetic Alterations Linked to Resistance to Antibody-Drug Conjugate in Triple-Negative Breast Cancer?
Long-Term Survival Update From Secondary Analysis of Stockholm Tamoxifen Trial
Can Statins Improve Outcomes in Patients With Triple-Negative Breast Cancer?
COVID-19 and Breast Cancer: Focus on Building Vaccine Acceptance
Manufacturer Withdraws Atezolizumab’s U.S. Indication in Triple-Negative Breast Cancer
FDA Issues Caution Statement on Use of Robotically Assisted Surgical Devices for Mastectomy
Postmenopausal Women With Breast Cancer: How Many Years of Adjuvant Endocrine Therapy Is Necessary?
Stromal Platelet-Derived Growth Factor Receptor-Beta Expression Biomarker for Early Breast Cancer
Preventing Trastuzumab-Induced Cardiotoxicity in Breast Cancer: Lisinopril or Carvedilol?
Patient Survey on Dosage Strategies and Tolerability of Breast Cancer Therapy
Estrogen Receptor Antagonist Under Study for Locally Advanced or Metastatic Breast Cancer
Managing Breast Cancer in Older Adults: An Updated International Policy Review
Can Serum Levels of Vitamin D at Diagnosis Predict Breast Cancer Prognosis?
Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.